Kornimate/medical-research-clean huggingface dataset:
value of flow cytometry in infectious point of care: feasibility study

Conditions: A Potential Infectious Respiratory Clinical Syndrome; Potential Clinical Urinary Infectious Syndrome; A Potential Clinical Abdominal Infection Syndrome

Summary: the purpose of this project is to validate the diagnostic orientation properties of two new biomarkers (cd64, cd169) for patients with infectious syndromes arriving in emergency departments. this prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (pr morange laboratory) without modifying the usual diagnostic and therapeutic procedures. the results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity. this study is the preliminary study, necessary to determine the detection characteristics of these biomarkers.

the detection and characterization of infectious events is a major challenge for emergency medicine. thus the possibility of quickly attributing an infectious origin to a febrile and/or inflammatory syndrome makes it possible to treat and refer the patient quickly. in addition, the ability to distinguish bacterial etiology from viral etiology provides a valuable additional indication for the clinician. this of the upmost importance for fragile populations such as elderly patients and in epidemic conditions such as influenza. a new rapid diagnostic guidance solution is proposed by the beckman coulter laboratory with the simultaneous assay of two biomarkers, one allowing the detection of a viral infectious process (cd169), the other of a bacterial infectious process (cd64). the combination of these two biomarkers, measured in 12 minutes by a new generation assay and flow cytometer, represents an opportunity for emergency services. to date, there is no study on the validation of this diagnostic orientation method. we propose to carry out a prospective, observational, non-interventional feasibility study to compare the results of these measurements with the usual diagnostic criteria combining the clinical signs, infectious testing, and biological data.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age presenting to the timone 2 emergency department with the association: * a fever\> 38 ° c or hypothermia \<36.5 ° c. * a potential clinical infectious syndrome is respiratory (cough, sputum, dyspnea), or urinary (potential urinary tract infection), or abdominal (potentially infectious diarrhea, potentially infectious pain syndrome) or neurological (meningitis potential) or cutaneous (erysipelas). exclusion criteria: * patients with clinical criteria that may increase other non-specific biomarkers and therefore not allow for subsequent comparison: * trauma * known inflammatory and autoimmune disease * infectious chronic viral, fungal or bacterial disease * antibiotic or anti viral treatment prior to admission * immunosuppressive treatment * neoplasia * extended burn * recent surgery (\<1 month)
riboflavin at 4ºc for the management of pain after crosslinking for keratoconus patients

Conditions: Keratoconus; Crosslinking

Summary: background: the objective of corneal collagen crosslinking (cxl) is to increase the binding of intrafibrillary and interfibrillary covalent bonds to improve the mechanical stability of the cornea and thus to stop the progression of corneal ectasias. although the vast majority of studies have described pain after photorefractive keratectomy (prk), the pathophysiological principle of pain is similar in cxl. from the anatomical point of view, the corneal epithelium is the most densely innervated and sensitive surface of the body, being 300-600 times greater than in the skin. the pain after cxl comes from several routes, the process begins with the epithelial rupture that generates exposure of the nerve endings, induces apoptosis and necrosis of the epithelial cells. subsequently an inflammatory cascade is initiated in which the different cytokines stimulate the nerve terminals. inflammatory mediators also activate the ion channels in the nerve membrane, and this process continues until the epithelium heals. additionally, exposure to uva rays can also cause nerve damage. the effect of local cold for pain management has already been reported in prk. by cooling the cornea, the release of chemical mediators and inflammation can be reduced. in the cxl radiation is transformed into several forms of energy: fluorescent radiation, chemical energy and, to a small extent, heat. the cxl process is energetically comparable to photosynthesis, in which the radiation energy is transformed into chemical energy (glucose) with the help of pigments (chlorophyll). the thermal effect is negligible in the photochemical method of cxl. justification: no method for the control of pain after crosslinking is considered ideal or universally accepted, the importance of this study lies in looking for an additional tool to reduce the most common postoperative complaint in a highly performed procedure worldwide. hypothesis: the application of riboflavin at 4oc reduces the pain assessment after the cxl. purpose: to evaluate the effect of the application of riboflavin at 4oc in the assessment of postoperative pain in patients undergoing cxl. materials and methods: prospective and interventional clinical study in patients older than 18 years with a diagnosis of keratoconus who underwent cxl, in the cornea and refractive surgery service of the ophthalmology institute fundación conde de valenciana.


Eligibility criteria:
inclusion criteria: * patients of any gender * older than 18 years * diagnosis of keratoconus who require management with crosslinking in both eyes for evidence of progression. exclusion criteria: * crosslinking without removal of epithelium or unilateral crosslinking. * patients with other ocular conditions different from keratoconus. * cognitive disability that limits the compression of the pain test as down syndrome, etc.

Keywords: crosslinking keratoconus cold pain
direct oral anticoagulants and management of blleding following dental extractions. a prospective cohort study.

Conditions: Post Operative Hemorrhage

Summary: evaluation of doacs treatment on post-extraction bleeding

consecutive patients requiring at least one dental extraction were enrolled. doacs regimen was either maintained or suspended. patients were classified in subgroups depending on the number of teeth extracted per procedure (≤ 3 or \> 3), the need for flap raising and the performance of osteotomy. bleeding was recorded intraoperatively, perioperatively at 20, 40, 60 and 80 minutes after the procedure, and in the first seven days post-operatively.

Eligibility criteria:
inclusion criteria: * age \>18 years * patients under pharmacological treatment with doacs * patients requiring at least one dental extraction * patients willing to take part in the study and to sign informed consent exclusion criteria: * patients below 18 years of age * patients treated with antiplatelet therapy or vitamin k antagonists * patients presenting with an international normalized ratio (inr) \>3.0 * patients suffering from congenital or acquired coagulopathies (e.g. haemophilia, coagulation factors deficiency, von willebrand disease, thrombocytopenia, cirrhosis)

Keywords: direct oral anticoagulants oral surgical procedure post-operative complications
barostim therapy™ in heart failure with preserved ejection fraction

Conditions: Heart Failure

Summary: the purpose of this registry (nct02876042) is to evaluate the effect of barostim therapy with the barostim neo system in the commercial setting in subjects recently implanted under the ce-marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (hfpef).

summary: the cvrx barostim therapy in heart failure with preserved ejection fraction (hfpef) registry will be performed with subjects who have been recently implanted with the barostim neo system in accordance with ce-mark approved criteria for resistant hypertension and have evidence of hfpef per the registry enrollment criteria. subjects must be enrolled within 30 days from implant but prior to therapy activation. up to 70 subjects will be enrolled at up to 10 sites. data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3 and 6 months after the device was implanted, at which time each subject will be exited from the registry. eligibility criteria: the ce-mark approved indications and contraindications for the barostim neo system in the treatment of resistant hypertension include: * indications * systolic blood pressure greater than or equal to 140 mmhg, and * resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications * contraindications * bilateral carotid bifurcations located above the level of the mandible * baroreflex failure or autonomic neuropathy * uncontrolled, symptomatic cardiac bradyarrhythmias * carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation

Eligibility criteria:
inclusion criteria: * sign an ethics committee (ec) approved informed consent form for the registry. * implanted with the barostim neo system in accordance with ce-mark approved indications and contraindications for resistant hypertension within 30 days prior to enrollment. * barostim therapy not yet chronically activated. * pre-implant echocardiogram with left ventricular ejection fraction ≥ 50% within 30 days prior to implant. * on stable, maximally-tolerated, guideline-directed cardiovascular medications for at least 30 days prior to enrollment. * objective evidence of heart failure according to the following criteria: * hospitalization for heart failure within 12 months prior to enrollment or * echocardiographic evidence of diastolic dysfunction (la volume index \>34 ml/m2 or e/e \>13) within 30 days prior to enrollment or * ntprobnp \> 220 pg/ml or bnp \> 80 pg/ml (in atrial fibrillation, ntprobnp \> 600 pg/ml or bnp \> 200 pg/ml) within 30 days prior to enrollment exclusion criteria: * heart failure secondary to a reversible or treatable condition such as, cardiac structural valvular disease, acute myocarditis and pericardial constriction. * heart failure secondary to right ventricular failure or right ventricular myocardial infarction.
role of droperidol in postoperative vomiting

Conditions: Vomiting

Summary: protocol title: role of low dose droperidol in postoperative vomiting purpose: evaluate the efficacy of droperidol to postoperative nausea and vomiting when administrated at the introduction to anesthesia, prior to surgery design: prospective, randomized, placebo-controlled study patient population: male or female subjects 18 years of age or older who are scheduled for laparoscopic cholecystectomy no. of subjects: 100 patients divided into two groups, estimated up to 6 months to enroll duration of treatment: prior operation duration of follow-up: follow-up will be performed for 24 hours postoperatively endpoints: to evaluate the effectiveness of low dose droperidol when administered prior surgery

in this prospective, randomized, placebo-controlled study, the researchers determined whether 0.625 mg (1/2 amp) iv droperidol given at the initiation of general anesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (ponv) in laparoscopic cholecystectomy population. one hundred patients receiving general anesthesia for laparoscopic cholecystectomy received droperidol 0.625 mg (1/2 amp) mg or placebo prior operation.

Eligibility criteria:
inclusion criteria: * patient more than 18 years old * patients scheduled for laparoscopic cholecystectomy * informed consent obtained from the patient exclusion criteria: * age \< 18 years old * contraindication to laparoscopic surgery * present a severe depressive syndrome * pregnancy women * trouble of cardiac rate * alcoholism * contra-indication for droperidol prescription

Keywords: nausea, vomiting vomiting episodes
safety and efficacy of oncoxin plus surafineb in hepatocellular carcinoma

Conditions: Quality of Life

Summary: oncoxin in combination with surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (hcc)

to assess therapeutic efficacy and safety of oncoxin plus surafenib in hepatocellular carcinoma to see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of oncoxin plus surafenib to see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of oncoxin plus surafenib to see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of oncoxin plus surafenib to see if there is improved survival in hepatocellular carcinoma patients after administration of oncoxin plus surafenib

Eligibility criteria:
inclusion criteria: * patients with hcc irrespective of etiology, age, gender and status of underlying liver disease. * patients with hcc who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * patients with hcc who have evidence of tumor metastasis * patients with hcc who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy. * patients with hcc in whom all possible treatment options have been exhausted. exclusion criteria: * patients with hcc who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * patients with hcc who have no evidence of tumor metastasis * patients with hcc who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy. * patients with hcc who are voluntarily unwilling to be included in the trial

Keywords: hepatocellular carcinoma oncoxin surafenib
dose-dependent effects of blueberry polyphenols on endothelial function in healthy individuals

Conditions: Endothelial Function

Summary: the purpose of this study is to assess the impact of acute blueberry polyphenol intake on endothelial function of healthy volunteers. specifically, the investigators plan to perform a randomised, double blind, cross-over human intervention trial using a blueberry drink to investigate the dose-dependent effects of blueberry polyphenols on blood vessel function using flow mediated dilation (fmd) to measure endothelial function. the study will not only measure the acute effects of flavonoid ingestion on vascular reactivity but will also assess plasma polyphenol metabolite levels.


Eligibility criteria:
inclusion criteria: * male * 18-40 years * healthy * signed consent form exclusion criteria: * blood pressure \> 140/90 mmhg * had suffered a myocardial infarction or stroke * suffers from any blood-clotting disorder * suffers from any metabolic disorders (e.g. diabetes or any other endocrine or liver diseases) * any dietary restrictions or on a weight reducing diet * allergies or intolerances to any foods * smoker * heavy drinker (\>21 units per week) * on any lipid-modifying medication * on any blood pressure lowering medication * on any medication affecting blood clotting * taking high dose fish oil supplements (greater then 1 g epa and dha per day) or high doses of antioxidant vitamins (greater then 800 μg vitamin a, 60 mg vitamin c, 10 mg vitamin e or 400 μg beta carotene) * taking probiotics, prebiotics, synbiotics, antibiotics or anti-inflammatory or blood lowering medication within a 2-month period prior to the study * planning on altering consumption of vitamin supplements/fish oil capsules during the course of the study * undertakes strenuous exercise \> 4 times per week for \> 1 hour per session * haemoglobin levels below reference range provided by the royal berkshire hospital

Keywords: flow-mediated dilation blueberry polyphenols dose-dependency
lung disease and its affect on the work of white blood cells in the lungs

Conditions: Alpha-1 Antitrypsin Deficiency; AAT Deficiency; AATD; Cystic Fibrosis (CF)

Summary: the purpose of this study is to look at how alpha-1-antitrypsin (aat) deficiency and cystic fibrosis (cf) affect white blood cells in the lungs, called macrophages, and their ability to work.

aat deficiency is a genetic disorder that affects around 100,000 people in the usa, including 1-3% of all people diagnosed with chronic obstructive pulmonary disease (copd). in aat deficient people diagnosed with copd, it was originally believed the cause of the disease was due to a lack of supply of alpha-1 antitrypsin. however, early information gathered in our laboratory suggests another cause of the development of copd and the progressing of the disease may be due to a malfunction in macrophages. cf is also a genetic disorder which affects 1/300 births among the caucasian population. one of the main symptoms of cf is inflammation of the lung tissue. lung macrophages play a major role in lung inflammation as well as in helping to resolve the inflammation. inflammation is an important defense of the body. it is the body's response to infection causing germs and things that may cause irritation, as well as, a way for the body to repair damaged tissue. we suggest that the effects of aat deficiency and cf decreases the inflammation response in the lungs and also restricts the ability of macrophages to correct that inflammation once it occurs.

Eligibility criteria:
inclusion criteria: * signed informed consent * male or female 18 years of age or older * negative pregnancy test for women of childbearing potential * hemoglobin \>12.5 g/dl measured on the day of participation * negative urine nicotine test exclusion criteria: * pregnancy or breastfeeding * weight \< 50 kg * history of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months * known hemoglobin \<12.5 g/dl within the past 90 days * systolic blood pressure \> 180 mmhg and/or diastolic blood pressure \>100 mmhg * poor venous access * large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking) * clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition) * psychiatric or cognitive disturbance or illness that would affect subject safety * current smoker

Keywords: macrophage alpha-1 antitrypsin deficiency cystic fibrosis
qualitative and quantitative hiv rna detection in saliva using the oragene rna kit

Conditions: HIV Infections

Summary: the purpose of this study is to determine if the oragene.rna kit is able to detect hiv rna in saliva.

there is an important need for a rapid, non-invasive, sensitive and specific method for detection of hiv rna, particularly in clinical settings in which patients at risk for hiv exposure are assessed and screened. a rapid and non-invasive method for quantitative testing of hiv rna would be also valuable to monitor suppression of hiv rna as a primary surrogate marker of combination antiretroviral therapy efficacy. an ottawa-based biotech company (dna genotek inc) has developed and sells to research and clinical labs world-wide a kit (oragene� dna self-collection kit) that permits the collection, stabilization at room temperature, and purification of dna present in saliva. they have recently developed a kit (oragene��rna) that is purported to stabilize rna in saliva, a non-invasive source of a biological fluid.

Eligibility criteria:
inclusion criteria: * four groups of 10 patients each will be recruited: * controls (hiv and hcv seronegative by previous testing) * hiv seropositive with hiv rna \&gt;1000 copies/ml and not on combination antiretroviral therapy. no concurrent hcv infection. * hiv seropositive with hiv rna \&lt;50 copies/ml as a consequence of combination antiretroviral therapy use. no concurrent hcv infection. * hiv seropositive with hiv rna \&gt;1000 copies/ml and not on combination antiretroviral therapy. hcv rna positive and not on antiviral therapy. exclusion criteria: * not fitting one of the 4 groups

Keywords: hiv rna
the effect of ondansetron during intramuscular ketamine use in children: a trial in emergency department

Conditions: Sedation and Analgesia; Side Effect of Drug

Summary: the purpose of this study is to evaluate the anti-emetic effect of oral ondansetron. for this evaluation, the investigators will perform a multi-center, double-blind, placebo-controled, randomized study. the investigators assumption is that oral ondansetron prior to intramuscular ketamine will reduce the occurrence of ketamine-induced vomiting.

methods * a multi-center, double-blind, placebo-controled, randomized study ( 4 tertiary hospital ed) * survey for the occurrence of vomiting at ed and after discharge primary outcome * the number of vomiting at ed and at home secondary outcome * parent's satisfaction and ed length of stay

Eligibility criteria:
inclusion criteria: * children under 18 years of age * children who are planned to admit ketamine intramuscular injection * children with asa classification class i or ii exclusion criteria: * don't want to enroll to study * children with condition of contraindication of ketamine (iicp, iiop, psychosis, brain tumor, thyroid disease, porphyria) * children with condition of contraindication of ondansetron (hypersensitivity to 5-ht3 antagonist, long qt syndrome, severe liver failure, obstructive ileus) * children under 3 months of age * children whose weight are over 30 kg * children managed by other drug with ketamine

Keywords: vomiting anti-emetics ketamine sedation
sleep quality, daytime sleepiness and insomnia in patients with endometriosis: a case-control study.

Conditions: Endometriosis; Sleep

Summary: this study included women referred to two academic centres for the diagnosis and treatment of endometriosis (cases) and women referred to our institutions because of routine gynaecologic consultations (controls). in this age-matched case-control study, the aimdy was to assess quality of sleep, the average daytime sleepiness and insomnia in patients with endometriosis by using three different self-reported questionnaires.


Eligibility criteria:
inclusion criteria: reproductive age surgical and histological diagnosis of rectovaginal endometriosis exclusion criteria: suspicion of endometriosis (based on evaluation of symptoms, gynaecological examination and transvaginal ultrasonography) history of infertility previous diagnosis of endometriosis gynaecological, intestinal and urological diseases causing abdominal pain (e.g. pelvic congestion syndrome, bladder pain syndrome) severe underlying comorbidities (cardiovascular, respiratory, renal, hematological, endocrine, hepatic, gastrointestinal, neurological, or psychiatric) pregnancy at any gestational age suspicion or diagnosis of oncological pathology use of gonadotropin releasing hormone analogues (gnrh-a) restless legs syndrome shift work use of antiallergic drugs narcotics refusal or inability to sign the informed consent form or complete the study questionnaires